Robert Kim

Robert Kim investigates how aberrant RNA splicing in cancer generates novel peptide neoantigens that can be recognized by the immune system and exploited for immunotherapy, expanding the neoantigen landscape beyond somatic mutations. His laboratory developed computational pipelines to predict splicing-derived neoantigens from RNA-seq data and validated their immunogenicity in patient tumors. He has contributed to clinical trials testing splicing neoantigen-based cancer vaccines. His work has broadened the definition of actionable cancer neoantigens for personalized immunotherapy.